Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
13 Maggio 2022 - 1:01PM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that Ted Schroeder, Chief Executive Officer at Nabriva,
will provide a company overview and business update at the H.C.
Wainwright Global Investment Conference. The presentation will be
available on-demand beginning on Tuesday, May 24 at 7:00 am ET.
Management will also host investor meetings May 24-26, 2022.
The presentation may be accessed by visiting the "Investors"
section of the Company's website under the "Events and
Presentations" tab at www.nabriva.com. A replay of the webcast will
be available for 90 days.
About Nabriva Therapeutics
plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva entered into an
exclusive agreement with subsidiaries of Merck & Co. Inc.,
Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO®
(tedizolid phosphate) in the United States and certain of its
territories. Nabriva Therapeutics received U.S. Food and Drug
Administration approval for XENLETA® (lefamulin injection,
lefamulin tablets), the first systemic pleuromutilin antibiotic for
community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics
is also developing CONTEPO™ (fosfomycin) for injection, a potential
first-in-class epoxide antibiotic for complicated urinary tract
infections (cUTI), including acute pyelonephritis.
CONTACT:
For Investors and MediaKim AndersonNabriva
Therapeutics plcir@nabriva.com
Grafico Azioni Nabriva Therapeutics (NASDAQ:NBRV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Nabriva Therapeutics (NASDAQ:NBRV)
Storico
Da Giu 2023 a Giu 2024